OncoResponse Announces Drug Discovery Collaboration with University of Texas MD Anderson Cancer Center to Advance ‘Elite Responder’ Derived Cancer Immunotherapies
SEATTLE, Washington - August 2, 2022 – OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced an additional drug discovery collaboration with the University of Texas MD Anderson Cancer Center.
The discovery effort will provide OncoResponse with tissue sample collection from ‘Elite Responders’ – patients who respond exceptionally well to cancer immunotherapy. Samples will be collected prior, during and after cancer immunotherapy treatment, providing unique insights into the immune profile of patients. MD Anderson will provide access to samples and physiologic, prognostic and genotypic data from patients along with oncology and translational medicine expertise.
“We are pleased to extend our drug development efforts derived from the clues of Elite Responders to develop therapies that may ultimately increase the number of patients who benefit from immunotherapy treatment. This new collaboration with MD Anderson Cancer Center will allow us to have access to tissue samples of Elite Responders before and after treatment. Such insight will allow us to further characterize why some individuals respond well to therapy and apply that knowledge to extend treatment modalities that will expand the impact of future cancer treatments,” said Clifford J. Stocks, CEO of OncoResponse. “OncoResponse remains committed to advancing novel and effective therapies that modulate the tumor microenvironment to help patients who desperately need additional treatment options.”
“These patient samples will allow us to gain insight into the changes within a patient’s immune repertoire during cancer immunotherapy. In our previous campaign with MD Anderson Cancer Center, the team at OncoResponse discovered and developed OR2805 – a fully human antibody that activates the tumor microenvironment – which is currently in Phase-1 dose escalation studies,” said Kamal Puri, PhD, Chief Scientific Officer at OncoResponse. “We look forward to this collaboration with MD Anderson Cancer Center to expand our pipeline of cancer immunotherapies.”
OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies. OR2805 is a fully human antibody discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy. Additional pipeline candidates that modulate suppressive macrophage activity are under development. OncoResponse is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Qatar Investment Authority, Redmile Group, Magnetar Group, Yonjin Venture, InterVest, Bering Capital, ARCH Venture Partners, Helsinn Investment Fund, Canaan Partners, GreatPoint Ventures, Takeda Ventures, Buchang Pharma, Alexandria Real Estate Equities and William Marsh Rice University. For more information please visit www.oncoresponse.com and follow us on LinkedIn and Twitter.